Hyperlipidaemia management after primary coronary artery bypass surgery: A survey of patients and general practitioners

Journal of Cardiovascular Risk

Volumn 6, Issue 4, 1999, Pages 263-267

  Goldsmith, Ira ^a   Lip, Gregory Y H ^b   Emsden, Kate ^a   Nugent, Ann ^a   Patel, Ramesh L ^a  

^a WALSGRAVE HOSPITAL   (United Kingdom)

^b UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Awareness; Coronary artery bypass surgery; General practitioners; Hyperlipidaemia; Patients; Secondary prevention

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; SIMVASTATIN; ANTILIPEMIC AGENT; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY BYPASS SURGERY; FEMALE; GENERAL PRACTITIONER; HEALTH SURVEY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MYALGIA; PRIORITY JOURNAL; RASH; RISK FACTOR; ALLERGIC RASH; DIET THERAPY; DRUG WITHDRAWAL; QUESTIONNAIRE;

EID: 0032829557     PISSN: 13506277     EISSN: None     Source Type: Journal    
DOI: 10.1177/204748739900600412     Document Type: Article

References (19)

1. Rose G, Hamilton PJ, Keen H, Reid DD, McCartney P, Jarrett RJ. Myocardial ischaemia, risk factors and death from coronary heart-disease. Lancet 1997; 1:105-109.
2. Martin MJ, Hulley SB, Browner WS, Kuller LH, Wentworth D. Serum cholesterol, blood pressure and mortality: implications from cohort of 361,662 men. Lancet 1986; ii:933-936.
3. Pekkanen J, Linn S, Heiss G, Suchindran CM, Leon A, Rifkind BM, et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men and without pre-existing cardiovascular disease. N Engl J Med 1990; 322:1700-1707.
4. Kannel WB. Range of serum cholesterol values in the population developing coronary artery disease. Am J Cardiol 1995; 76:69C-77C.
5. Rossouw JE. Lipid-lowering interventions in angiographic trials. Am J Cardiol 1995; 76:86C-92C.
6. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389.
7. Shepherd J, Cobbe SM, Ford I, Isler CG, Lorimer AR, Macfarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N Engl J Med 1995; 333:1301-1307.
8. Byington RP, Jukema JW, Salonen JT, Pitt B, Bruschke AV, Hoen H, et al. Reduction in cardiovascular events during pravastatin therapy: pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation 1995; 92:2419-2425.
9. ASPIRE Steering Group. A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events), principal results. Heart 1996; 75:334-342.
10. Daida H, Yokoi H, Mokuno H, Satoh H. Kottke TE, Hosoda Y, et al. Relation of saphenous vein graft obstruction to serum cholesterol levels. J Am Coll Cardiol 1995; 25:193-197.
11. Campeau L, Enjalbert M, Lesperance J, Bourassa MG, Kwiterovich P, Wacholder S, et al. The relation of risk factors to the development of atherosclerosis in saphenous vein bypass grafts and the progression of disease in the native circulation: a study 10 years after aortocoronary bypass surgery. N Engl J Med 1984; 311:1329-1332.
12. Campeau L, Knatterud GL, Domanski M, Hunninghake DG, White CW, Goller NL, et al. for the Post-CABG Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997; 336:153-162.
13. Violaris AG, Melkert R, Serruys PW. Influence of serum cholesterol and cholesterol subfractions on restenosis after successful coronary angioplasty. A quantitative angiographic analysis of 3336 lesions. Circulation 1994; 90:2267-2279.
14. Tedoriya T, Kawasuji M, Sakakibara N, Ueyama K, Tekemura H, Watanabe Y. Coronary artery bypass surgery in patients with familial hypercholesterolaemia. Nippon Kyobu Geka Gakkai Zasshi 1992; 40:1095-1099.
15. Betteridge DJ, Dodcon PM, Durrington PN, Hughes EA, Laker ME, Nicholls DP, et al. Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association. Postgrad Med J 1993; 69:359-369.
16. NHS Executive. SMAC statement on use of statins. Wetherby (West Yorkshire): Department of Health, 1997 (Executive Letter: EL(97)41).
17. Research Committee to the Medical Research Council. Low fat diet in myocardial infarction. A controlled trial. Lancet 1965; ii:501-504.
18. Woodhill JM, Palmer AJ, Leelarthaepin B, McGilchrist C, Blacket RB. Low fat, low cholesterol diet in secondary prevention of coronary artery disease. Adv Exp Med Biol 1978; 109:317-330.
19. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al., for the Cholesterol and Recurrent Events trial investigators (CARE). The effect of pravastatin in coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335:1001-1009.